Samantha Semenkow

Stock Analyst at Citigroup

(0)
# 4909
Out of 5,370 analysts
52
Total ratings
20.00%
Success rate
-22.71%
Average return
20 Stocks
Name Action PT Current % Upside Ratings Updated
PRME Prime Medicine
Downgrades: Neutral
10 2
1.5 0% 3 May 27, 2025
CABA Cabaletta Bio
Maintains: Buy
17 13
1.94 570.1% 3 May 16, 2025
ALLO Allogene Therapeutic...
Maintains: Buy
8 4
1.36 194.12% 3 May 15, 2025
ARGX argenx
Maintains: Strong Buy
796 803
551.73 45.54% 6 May 9, 2025
GPCR Structure Therapeuti...
Initiates Coverage On: Buy
60
20.62 190.98% 1 May 2, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
7 5
4.37 14.42% 3 Mar 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
6 3
n/a n/a 2 Jan 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
12
3.31 262.54% 1 Dec 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
27 31
23.66 31.02% 2 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
8 15
2.52 495.24% 2 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Buy
80
n/a n/a 2 Jun 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
10 14
2.87 387.8% 6 May 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
16 15
2.15 597.67% 4 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
9 12
n/a n/a 2 Apr 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
72
42.92 67.75% 1 Dec 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
46
n/a n/a 1 Dec 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
33 50
15.48 223% 3 Sep 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
60 56
16.62 236.94% 3 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
2 1
n/a n/a 3 May 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
n/a n/a 1 May 3, 2023